The oncology biologics sector is witnessing shifting dynamics as anti-VEGF therapies adapt to biosimilar competition and pricing policies. Avastin Market Growth remains a high-value asset within this evolving landscape, with industry trends driven by emerging markets, regulatory shifts, and novel combination regimens.
Market Size and Overview
The Global Avastin Market is estimated to be valued at USD 1,348.8 Mn in 2025 but is expected to decline to USD 812.9 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of -7.1% from 2025 to 2032.
• Avastin Market size contraction reflects biosimilar entry, pricing pressures, and shifting treatment guidelines.
• Despite a decline in market revenue, the industry scope continues to pivot toward combination therapies and emerging-market adoption, per the latest Avastin Market report.
Current Event & Its Impact on Market
I. Patent Expiry and Biosimilar Launches in Key Regions
A. EU Approval of Mvasi (Amgen) – Potential impact on Market
B. US Launch of Zirabev (copyright) – Potential impact on Market
C. Japan’s Fast-Track Pathway Utilization – Potential impact on Market
II. Pricing and Reimbursement Reforms
A. Germany’s Reference-Price Cuts in 2025 – Potential impact on Market
B. China’s National Procurement Tender – Potential impact on Market
C. Brazil’s Public-Sector Price Negotiations – Potential impact on Market
Impact of Geopolitical Situation on Supply Chain
• Case Study: Russia–Ukraine Conflict Disrupts Raw Material Sourcing
– Key raw materials for biologic buffers and cell-culture reagents traditionally shipped via Black Sea ports faced delays in Q3 2024.
– Manufacturers in Western Europe experienced 20% longer lead times, raising production costs by 8%.
– Strategic inventory build-up and dual-sourcing policies in H1 2025 mitigated further supply-chain interruptions but added 5% to working-capital requirements.
SWOT Analysis
Strengths
• Proven clinical efficacy in colorectal, ovarian, and lung cancers drives stable prescribing despite price erosion.
• Established brand recognition bolsters market share in developed regions, supporting continued business growth.
• Extensive real-world data and robust pharmacovigilance strengthen payor confidence and facilitate reimbursement.
Weaknesses
• High treatment cost remains a restraint in emerging markets, limiting market opportunities for hospital and clinic segments.
• Patent expiry in major geographies has led to rapid biosimilar uptake, eroding Avastin Market share and market revenue.
• Intravenous administration necessitates infusion center access, constraining patient convenience and market dynamics.
Opportunities
• Expansion into combination regimens with immunotherapies and targeted agents could spur renewed market growth strategies.
• Licensing partnerships in Asia Pacific and Latin America offer potential to recapture industry share via tailored pricing models.
• Digital monitoring platforms and home-care infusion services can enhance patient adherence and broaden market segments.
Threats
• Intensifying biosimilar competition may impose additional market restraints on pricing and hospital procurement tenders.
• Regulatory scrutiny around immunogenicity and interchangeability could delay biosimilar launches and impact market forecast.
• Ongoing economic headwinds and healthcare budget cuts pose challenges to market research–driven adoption of high-cost therapies.
Key Players
Genentech (Roche)
Amgen
copyright
Samsung Bioepis
Biocon
Celltrion
Sandoz (Novartis)
Merck & Co.
Dr. Reddy’s Laboratories
Teva Pharmaceutical Industries
Zydus Cadila
Cipla
Fresenius Kabi
Mylan
Apotex
Stada Arzneimittel
Intas Pharmaceuticals
Biogen
• In 2024, Amgen and Samsung Bioepis expanded manufacturing capacity in Europe, reducing biosimilar lead times by 15%.
• copyright and Biocon signed a strategic licensing agreement in Q2 2025 to co-market Zirabev across APAC, targeting a 12% revenue uplift in emerging markets.
• Roche invested in real-world evidence platforms in late 2024, enhancing payor negotiations and sustaining Avastin Market report visibility.
FAQs
1. Who are the dominant players in the Avastin Market?
Key market players include Genentech (Roche), Amgen, copyright, Samsung Bioepis, Biocon, and Sandoz, all driving market growth through biosimilar launches and strategic partnerships.
2. What will be the size of the Avastin Market in the coming years?
The Avastin Market size is projected to contract from USD 1,348.8 Mn in 2025 to USD 812.9 Mn by 2032 at a –7.0% CAGR, per the latest market forecast.
3. Which end-user industry has the largest growth opportunity?
Hospital infusion centers in Asia Pacific and Latin America represent the largest market opportunities, driven by rising cancer incidence and improved reimbursement frameworks.
4. How will Avastin Market development trends evolve over the next five years?
Trends will include expanded combination regimens with immuno-oncology agents, increased digital health integration, and pricing models tailored to emerging-market dynamics.
5. What is the nature of the competitive landscape and challenges in the Avastin Market?
The landscape is marked by aggressive biosimilar launches, price competition, and payor-driven procurement reforms, presenting challenges in maintaining market share.
6. What go-to-market strategies are commonly adopted in the Avastin Market?
Strategies include strategic licensing in regional markets, differential pricing agreements, real-world evidence generation, and partnerships with infusion-service providers to enhance patient access and business growth.
Get more insights on – Avastin Market
Read more articles related to this industry-
Recent Developments in Active Pharmaceutical Ingredients Industry
Regulatory Standards for Active Pharmaceutical Ingredients: Ensuring Safety and Compliance
How Active Pharmaceutical Ingredients Are Manufactured: Key Processes and Techniques
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
copyright src="chrome-extension://fpjppnhnpnknbenelmbnidjbolhandnf/content_script_web_accessible/ecp_regular.js" type="text/javascript">